ClinicalTrials.govpublic full text
A Study to Evaluate the Effect of Obicetrapib/Ezetimibe 10 mg Fixed-Dose Combination or Obicetrapib 10 mg Daily on Top of Guideline-Recommended Lipid-Lowering Therapy in Participants With Type 2 Diabetes and/or Metabolic Syndrome
lipidemia, type 2 diabetes (t2dm), metabolic syndrome (mets), interventional, phase3
This document is indexed with metadata only — full text is not available in the archive for this record.
Open the official source ↗Related documents
Record · ID 911895
Retrieved via
Conceptio — every document is proof-bundled with source, license, and retrieval metadata.